News Seelos Therapeutics, Inc.

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Market Closed - OTC Markets 20:25:32 01/06/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

All News

Mentions Relevance

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
25/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
07/10/24	Seelos Therapeutics : Material Event Form 8 K	PU
27/09/24	Seelos Therapeutics : Announces Postponement of its Annual Meeting of Stockholders Form 8 K	PU
27/09/24	Seelos Announces Postponement of its Annual Meeting of Stockholders	PR
25/09/24	Seelos Therapeutics Announces 1-for-16 Reverse Stock Split	PR
25/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24/09/24	Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study	MT
24/09/24	Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD	PR
15/08/24	Seelos: Q2 Earnings Snapshot	AQ
15/08/24	Seelos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/05/24	Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	PR
16/05/24	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI